Anna C. Pavlick, DO

Anna C. Pavlick, BSN, MSc, DO, MBA, is a professor of medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine; as well as the founding director of the Cutaneous Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian

Articles

RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA

May 5th 2025

Dr Pavlick discusses the investigation of RP1 plus nivolumab in patients with advanced melanoma who have received prior immune checkpoint inhibition.

Dr Pavlick on RP1 Plus Nivolumab in PD-1 Inhibitor–Pretreated Melanoma

April 29th 2025

Anna C. Pavlick, BSN, MSc, DO, MBA, discusses efficacy data with RP1 plus nivolumab in patients with melanoma who had progressed on PD-1–directed therapy.

Closing Thoughts on Intralesional Therapy for Melanoma and CSCC

May 24th 2023

A panel of skin cancer experts offer closing thoughts on intralesional therapy for treating melanoma and CSCC.

Tumor-Directed Oncolytic Therapies for Melanoma and CSCC

May 17th 2023

An expert panel discusses the use of tumor-directed oncolytic therapies for melanoma and cutaneous squamous cell carcinoma.

Treating Patients with High-Risk Melanoma

May 17th 2023

A comprehensive overview of treatment approaches for patients with high-risk melanoma.

Meaningful End Points for Patients with Metastatic Melanoma

May 10th 2023

Experts on skin cancer discuss valuable end points for determining successful treatments for patients with metastatic melanoma.

Deciding Between Melanoma Therapy Options

May 10th 2023

A panel of skin cancer experts share their thoughts on treatment selection for patients with melanoma.

BRAF/MEK Dual Inhibitors for Melanoma

May 3rd 2023

An expert panel analyzes BRAF/MEK dual inhibitor therapy for the treatment of melanoma.

Factors that Impact Treatment Selection for Melanoma

May 3rd 2023

Anna C. Pavlick, DO, discusses factors that impact treatment selection for patients with melanoma.

Future Treatment Landscape for Squamous Cell Carcinoma

April 26th 2023

Expert oncologists look to the future of treatment for cutaneous squamous cell carcinoma.

Treatment Duration Considerations for CSCC

April 26th 2023

Skin cancer expert Anna C. Pavlick, DO, discusses treatment duration approaches for cutaneous squamous cell carcinoma.

CSCC Treatment Options: Cemiplimab and Pembrolizumab

April 19th 2023

Nikhil Khushalani, MD, gives a comprehensive overview of cemiplimab and pembrolizumab for treating CSCC.

Choosing Systemic Therapies for Patients with Unresectable or Metastatic CSCC

April 19th 2023

Anna C. Pavlick, DO, overviews systemic therapy options for patients with unresectable or metastatic CSCC.

Multidisciplinary Management of CSCC

April 12th 2023

Nikhil Khushalani, MD, discusses the multidisciplinary team approach to treating patients with cutaneous squamous cell carcinoma.

Unmet Needs and Prognosis for CSCC and Melanoma

April 12th 2023

Skin cancer experts discuss prognosis and unmet needs in the cutaneous squamous cell carcinoma and melanoma treatment spaces.

Dr Pavlick on the Mechanisms of Action of RP1 in Cutaneous Melanoma

April 3rd 2023

Anna C. Pavlick, DO, discusses the mechanism of action of vusolimogene oderparepvec in patients with anti–PD-1–failed cutaneous melanoma.

Overview of Cutaneous Squamous Cell Carcinoma and Melanoma

March 31st 2023

A panel of skin cancer experts give an overview of cutaneous squamous cell carcinoma and melanoma.

Dr. Pavlick on the IGNYTE Trial in Patients With Melanoma Following Anti–PD-1 Progression

March 8th 2023

Anna C. Pavlick, DO, discusses the phase 2 IGNYTE trial examining vusolimogene oderparepvec in combination with nivolumab in 3 tumor-specific cohorts, including 1 featuring patients with anti–PD-1–failed cutaneous melanoma.

Dr. Pavlick on Addressing Unmet Needs in Melanoma Through Ongoing Investigation

March 2nd 2023

Anna C. Pavlick, DO, discusses how ongoing research efforts at Weill Cornell Medicine are attempting to ameliorate unmet needs in melanoma.

Dr. Pavlick on the Benefit of Neoadjuvant Immunotherapy in Resectable Melanoma

January 16th 2023

Anna C. Pavlick, DO, discusses the potential benefit of neoadjuvant immunotherapy prior to surgical resection, according to results from the phase 2 SWOG S1801 trial.